Gland Pharma Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7ngpj07jvz5djzb8ulomd59q.pdf

Key Takeaways


Cenexi Turnaround

Srinivas Sadu: "Fontenay site, I think, we were struggling to deliver the demand and the line which we have added in March that kind of helped us to catch up with some of the back orders and also increase the capacity. So that was added in Fontenay and brought into green."

Base Business Margin Expansion


U.S. Business & Launch Momentum

Srinivas Sadu: "everybody is now keeping fingers crossed when and how much they will charge because the market says for generic there may be exemption, but mostly on the branded side they may put/impose large tariffs."

GLP-1 Capacity Build & Commercialization Timeline

Shyamakant Giri: "We are talking to four types of customers - Indian customers for global market, Global customers for India market, Indian customer for Indian market. And finally, we are talking to also some more players for global markets."

Liraglutide & Peptide Launches


Other Markets & Partnerships


Guidance & Commitments

CommitmentSpecificsTimeline
Cenexi EBITDA positiveTurn EBITDA positive after seasonal Q2 dipFrom October (Q3 FY'26) onward
Cenexi margin trajectoryRamp to low teens or high single digits EBITDANo specific date; "ramp it up slowly"
U.S. mid-teen growthAchieve mid-teen growth for full yearFY'26
Pen/cartridge capacity utilization~2 crore units utilizedFY'27 (first year)
GLP-1 capacity commercializationNew 10 crore capacity ready; majority of utilizationReady by Mar/Apr '26; majority filling from FY'29-FY'30
CMS dry powder launchDossiers submitted next quarter; products launchBeginning of next year (Europe and other markets)
New prefilled syringe line (Herouville)OperationalBeginning of calendar year 2026
New lyophilizers (Braine-l'Alleud)Qualifications concludedEnd of calendar year 2025
Generic Vyzulta launchSubject to settlement and patentFY'29

Key Metrics

MetricQ1 FY26
Consolidated revenue₹1,505.6 crore, +7% YoY
Consolidated EBITDA₹367.8 crore, +39% YoY
Consolidated EBITDA margin24%, up from 19% in Q1 FY25
Consolidated gross margin65%, up from 60% in Q1 FY25
Net profit₹215.5 crore, +50% YoY
PAT margin14%, up from 10% in Q1 FY25
Base business revenue growth (ex-Cenexi)3% YoY
Base business EBITDA margin (ex-Cenexi)35%, up from 29% in Q1 FY25
Base business gross margin (ex-Cenexi)59%, up from 53% in Q1 FY25
U.S. revenue₹744.3 crore, 49% of total revenue
Other regulated markets revenue growth+34% YoY, 27% of total revenue
Rest of World revenue₹297.8 crore, +5% YoY and +24% QoQ, 20% of total revenue
India revenue₹59.4 crore, 4% of total revenue
Cenexi revenueEUR 48 million
Cenexi EBITDAEUR 0.9 million, breakeven achieved
Cenexi gross margin80%, up from 78% in Q1 FY25
R&D expenditure₹46 crore, 4.4% of base business revenue
U.S. new product launches9 new molecules launched
ANDA filings and approvals1 ANDA filed, 9 approved
RTU bag portfolio filed in U.S.20 products filed, 14 approved
Co-development portfolio15 products, including 7 505(b)(2) and 8 ANDAs
Cash and equivalents (group level)₹3,013.9 crore as of June 30, 2025, including ₹396 crore non-callable deposit
Cash flow from operations₹262 crore
Cash conversion cycle161 days, improved from 172 days at FY25 end
Total capex₹78.6 crore
Effective tax rate (standalone)25.7%
Pen and cartridge capacity4 crore units operational, expanding to over 14 crore units
Cenexi order bookEUR 85–90 million